Atossa Therapeutics, Inc. - Common Stock (ATOS)

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.

The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD.

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today.

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.

With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.

ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

One in eight women will be diagnosed with breast cancer during

Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and